BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35689561)

  • 1. Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma.
    Wu G; Wang Y; Wan Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24538. PubMed ID: 35689561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma.
    Song X; Chen Q; Wang J; Mao Q; Xia W; Xu L; Jiang F; Dong G
    J Cell Mol Med; 2022 Jan; 26(2):436-448. PubMed ID: 34877770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
    Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
    Front Immunol; 2022; 13():876355. PubMed ID: 35837383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
    Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
    Wang Y; Zhang G; Wang R
    Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases.
    Zhou Y; Shi X; Chen H; Mao B; Song X; Gao L; Zhang J; Yang Y; Zhang H; Wang G; Zhuang W
    Biomed Res Int; 2021; 2021():5557649. PubMed ID: 34337026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
    Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
    BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 12. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
    BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
    Chen J; Fu Y; Hu J; He J
    Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a hypoxic immune microenvironment associated gene-based model for prognosis prediction of lung adenocarcinoma.
    Lin GY; Wu S; Gao ZS; Wu LH; Yan JJ; Guo XQ; Wang ZY
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3807-3826. PubMed ID: 35731050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.